Author:
Lowres Nicole,Krass Ines,Neubeck Lis,Redfern Julie,McLachlan Andrew J.,Bennett Alexandra A.,Freedman S. Ben
Funder
National Heart Foundation
NHMRC and National Heart Foundation
NHMRC
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy
Reference43 articles.
1. Leyden JM, Kleinig TJ, Newbury J, Castle SF, Cranefield J, Anderson CS, et al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke. 2013;44(5):1226–31.
2. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103–8.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.
4. Camm AJ, Lip GYH, Caterina RD, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.
5. Stott DJ, Dewar RI, Garratt CJ, Griffith KE, Harding NJ, James MA, et al. RCPE UK consensus conference on ‘approaching the comprehensive management of atrial fibrillation: evolution or revolution?’. J R Coll Phys Edinb. 2012;42(Suppl 18):3–4.
Cited by
65 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献